Consequently, ibrutinib, an FDA-approved BTK inhibitor for hematological malignancies, has been repurposed as a candidate for GBM treatment, demonstrating inhibitory effects on the proliferation, stemness, and invasiveness of GBM cell lines and TSs. The gene discussed is BTK; the disease is glioblastoma.